Cargando…
Pioglitazone and sulfonylureas: effectively treating type 2 diabetes
Type 2 diabetes is characterised by a gradual decline in glycaemic control and progression from oral glucose-lowering monotherapy to combination therapy and exogenous insulin therapy. Functional decline of the insulin-secreting β-cells is largely responsible for the deterioration in glycaemic contro...
Autor principal: | Hanefeld, M |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1974826/ https://www.ncbi.nlm.nih.gov/pubmed/17594390 http://dx.doi.org/10.1111/j.1742-1241.2007.01361.x |
Ejemplares similares
-
The TOSCA.IT Trial: A Study Designed to Evaluate the Effect of Pioglitazone Versus Sulfonylureas on Cardiovascular Disease in Type 2 Diabetes
por: Vaccaro, Olga, et al.
Publicado: (2012) -
Consensus Recommendations on Sulfonylurea and Sulfonylurea Combinations in the Management of Type 2 Diabetes Mellitus – International Task Force
por: Kalra, Sanjay, et al.
Publicado: (2018) -
Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: A randomized controlled trial (the RECORD study)
por: Komajda, Michel, et al.
Publicado: (2008) -
Incidence of Bladder Cancer in Patients With Type 2 Diabetes Treated With Metformin or Sulfonylureas
por: Mamtani, Ronac, et al.
Publicado: (2014) -
Sulfonylurea: Personalized Medicine for Type 2 Diabetes
por: Hwang, You-Cheol
Publicado: (2015)